One-center, Randomized, Placebo-controlled, Double Blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses (5-1000 mg, Solution) of BAY1214784 Including the Relative Bioavailability of BAY1214784 Administered as Solution With Two Different Concentrations in 56 Healthy Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2015
At a glance
- Drugs BAY 1214784 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 10 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 05 Sep 2014 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 05 Sep 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.